Global News

Illumina, Telegraph Hill Partners launch Verogen

Tuesday, August 29, 2017

Illumina announced plans with Telegraph Hill Partners (THP), a San Francisco-based venture capital and growth equity firm, to establish Verogen. The independent new company has certain exclusive rights to provide Illumina’s forensic sequencing technology to forensic customers, including for criminal casework and other human and nonhuman forensic applications. The creation of Verogen enables an unprecedented focus on accelerating growth of Illumina’s leading next-generation sequencing (NGS) technology in the forensic genomics market.

[Read More]

labfolder expands, collaborates with the German Accelerator Life Sciences

Tuesday, August 29, 2017

labfolder and the German Accelerator Life Sciences (GALS), an initiative supported by the German Federal Ministry for Economic Affairs and Energy (BMWi), announced the initiation of an extensive collaboration supporting the company’s expansion into the North American markets. With thousands of users and a growing number of customers in the U.S. already, the newly established Cambridge office will accelerate those efforts and support customer relations.

[Read More]

Shire, MicroHealth to address hemophilia A and B patient needs

Tuesday, August 29, 2017

Shire, a biotech leader in rare diseases, announced a collaboration with MicroHealth to support a free and secure care monitoring tool for hemophilia A and B patients with inhibitors and their care teams. MicroHealth, a digital health company co-created by a hemophilia patient, developed the tool, in the form of an app, to help improve hemophilia patient care and outcomes through the ability to set reminders, track, store and selectively share personal health data, including photos and bleed alerts, with care team members. Shire’s collaboration with MicroHealth will help the start-up customize the tool with new features and information specifically for the 5-7% of hemophilia patients with inhibitors. Both companies remain independent in this collaboration and Shire does not have access to any patient, caregiver or other third-party data through this collaboration.

[Read More]

NIH Clinical Center receives 2017 Excellence Award for patient emotional support

Tuesday, August 29, 2017

The National Research Corporation (NRC) Health has selected the NIH Clinical Center as a recipient of its 2017 Excellence Award, having earned the highest ratings in overall satisfaction by patients and their families in the category of Emotional Support, among 426 eligible facilities. Each year, NRC Health recognizes top-performing hospitals and health systems that have exhibited an exceptional commitment to understanding each individual patient’s complete care journey.

[Read More]

PPD, HealthCore expand real-world research capabilities

Monday, August 28, 2017

PPD and HealthCore are building upon their existing collaboration to include Evidera, PPD’s peri- and post-approval business unit. The addition of Evidera will help enable the companies to address post-marketing safety commitments in Europe and the U.S., and expand the relationship to include other studies evaluating outcomes in real-world settings.

[Read More]

The Max Foundation, Tanner Pharma partner on drug distribution model

Monday, August 28, 2017

The Max Foundation, an international non-governmental organization dedicated to increasing global access to treatment, care and support for people living with cancer, and Tanner Pharma Group, a global pharma services company that specializes in patient access to critical medication, have partnered to create an innovative distribution model designed to effectively deliver humanitarian donations of oncology products to identified patients in need in low resource countries.

[Read More]

Gilead Sciences to acquire Kite Pharma for $11.9B

Monday, August 28, 2017

Gilead Sciences and Kite Pharma announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Kite for $180.00 per share in cash. The transaction, which values Kite at approximately $11.9 billion, was unanimously approved by both the Gilead and Kite Boards of Directors and is anticipated to close in the fourth quarter of 2017. The transaction will provide opportunities for diversification of revenues, and is expected to be neutral to earnings by year three and accretive thereafter.

[Read More]